You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國疫苗協會料年底前新冠疫苗有望接種近七成國人 明年產能50億劑
阿思達克 04-08 17:03
據《北京日報》報道,在由北京大學主辦的「新冠疫苗與疫苗產業國際化」研討會上,中國疫苗行業協會會長封多佳披露,明年中國新冠疫苗年產能將達到約50億劑,而在今年底前近七成國人有望陸續進行接種。

封多佳則表示,截至目前,中國國產新冠疫苗在國內的使用量超過1.3億劑,而出口數量也超過了1億劑,涉及百餘個國家。

科興控股(香港)總經理楊光在會上介紹,目前科興的疫苗年產能已達20億劑,國內還有不少疫苗企業也在朝著年產能10億乃至20億劑規模邁進,中國疫苗產品和產業出海已站在更新的高度上,達到了更高的標準。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account